Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation.

Chatonnet F, Pignarre A, Sérandour AA, Caron G, Avner S, Robert N, Kassambara A, Laurent A, Bizot M, Agirre X, Prosper F, Martin-Subero JI, Moreaux J, Fest T, Salbert G.

Haematologica. 2019 Jun 20. pii: haematol.2019.222133. doi: 10.3324/haematol.2019.222133. [Epub ahead of print]

2.

Cytosine modifications modulate the chromatin architecture of transcriptional enhancers.

Mahé EA, Madigou T, Sérandour AA, Bizot M, Avner S, Chalmel F, Palierne G, Métivier R, Salbert G.

Genome Res. 2017 Jun;27(6):947-958. doi: 10.1101/gr.211466.116. Epub 2017 Apr 10.

3.

Inactivation of the Nuclear Orphan Receptor COUP-TFII by Small Chemicals.

Le Guével R, Oger F, Martinez-Jimenez CP, Bizot M, Gheeraert C, Firmin F, Ploton M, Kretova M, Palierne G, Staels B, Barath P, Talianidis I, Lefebvre P, Eeckhoute J, Salbert G.

ACS Chem Biol. 2017 Mar 17;12(3):654-663. doi: 10.1021/acschembio.6b00593. Epub 2017 Jan 13.

PMID:
28059499
4.

A Point Mutation in a lincRNA Upstream of GDNF Is Associated to a Canine Insensitivity to Pain: A Spontaneous Model for Human Sensory Neuropathies.

Plassais J, Lagoutte L, Correard S, Paradis M, Guaguère E, Hédan B, Pommier A, Botherel N, Cadiergues MC, Pilorge P, Silversides D, Bizot M, Samuels M, Arnan C, Johnson R, Hitte C, Salbert G, Méreau A, Quignon P, Derrien T, André C.

PLoS Genet. 2016 Dec 29;12(12):e1006482. doi: 10.1371/journal.pgen.1006482. eCollection 2016 Dec.

5.

Dynamic estrogen receptor interactomes control estrogen-responsive trefoil Factor (TFF) locus cell-specific activities.

Quintin J, Le Péron C, Palierne G, Bizot M, Cunha S, Sérandour AA, Avner S, Henry C, Percevault F, Belaud-Rotureau MA, Huet S, Watrin E, Eeckhoute J, Legagneux V, Salbert G, Métivier R.

Mol Cell Biol. 2014 Jul;34(13):2418-36. doi: 10.1128/MCB.00918-13. Epub 2014 Apr 21.

6.

Dynamic hydroxymethylation of deoxyribonucleic acid marks differentiation-associated enhancers.

Sérandour AA, Avner S, Oger F, Bizot M, Percevault F, Lucchetti-Miganeh C, Palierne G, Gheeraert C, Barloy-Hubler F, Péron CL, Madigou T, Durand E, Froguel P, Staels B, Lefebvre P, Métivier R, Eeckhoute J, Salbert G.

Nucleic Acids Res. 2012 Sep 1;40(17):8255-65. Epub 2012 Jun 22.

7.

Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers.

Sérandour AA, Avner S, Percevault F, Demay F, Bizot M, Lucchetti-Miganeh C, Barloy-Hubler F, Brown M, Lupien M, Métivier R, Salbert G, Eeckhoute J.

Genome Res. 2011 Apr;21(4):555-65. doi: 10.1101/gr.111534.110. Epub 2011 Jan 13.

8.

Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.

Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, Howard D, Dole WP.

J Clin Pharmacol. 2008 Nov;48(11):1323-38. doi: 10.1177/0091270008323258. Epub 2008 Sep 10.

PMID:
18784280
9.

Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers.

Huang HL, Vaidyanathan S, Yeh CM, Bizot MN, Dieterich HA, Dole WP, Howard D.

Curr Med Res Opin. 2008 Sep;24(9):2449-56. doi: 10.1185/03007990802285763 . Epub 2008 Jul 24.

PMID:
18662494
10.

A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.

Ayalasomayajula S, Tchaloyan S, Yeh CM, Bizot MN, Dieterich HA, Howard D, Dole WP.

Curr Med Res Opin. 2008 Mar;24(3):717-26. doi: 10.1185/030079908X260934. Epub 2008 Jan 29.

PMID:
18234150
11.

Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers.

He YL, Sabo R, Sunkara G, Bizot MN, Riviere GJ, Leon S, Ligueros-Saylan M, Dole WP, Howard D.

J Clin Pharmacol. 2007 Aug;47(8):998-1004.

PMID:
17660482
12.

Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment.

Vaidyanathan S, Bigler H, Yeh C, Bizot MN, Dieterich HA, Howard D, Dole WP.

Clin Pharmacokinet. 2007;46(8):661-75.

PMID:
17655373
13.

Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects.

Vaidyanathan S, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, Howard D, Dole WP.

J Clin Pharmacol. 2007 Apr;47(4):453-60.

PMID:
17389554
14.

Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.

Vaidyanathan S, Warren V, Yeh C, Bizot MN, Dieterich HA, Dole WP.

J Clin Pharmacol. 2007 Feb;47(2):192-200.

PMID:
17244770
15.
16.
17.

Pharmacokinetic interaction between verapamil and everolimus in healthy subjects.

Kovarik JM, Beyer D, Bizot MN, Jiang Q, Allison MJ, Schmouder RL.

Br J Clin Pharmacol. 2005 Oct;60(4):434-7.

18.

Blood concentrations of everolimus are markedly increased by ketoconazole.

Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, Schmouder RL.

J Clin Pharmacol. 2005 May;45(5):514-8.

PMID:
15831774
19.

Effect of multiple-dose erythromycin on everolimus pharmacokinetics.

Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, Schmouder RL.

Eur J Clin Pharmacol. 2005 Mar;61(1):35-8. Epub 2005 Jan 27.

PMID:
15785960
20.

Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation.

Kovarik JM, Tedesco H, Pascual J, Civati G, Bizot MN, Geissler J, Schmidli H.

Ther Drug Monit. 2004 Oct;26(5):499-505.

PMID:
15385832
21.

JAHK: a low frequency antigen associated with the rG complex of the Rh blood group system.

Green C, Coghlan G, Bizot M, Kasulke D, Bombail-Girard M, Wallace M, Lomas-Francis C, Daniels G.

Transfus Med. 2002 Feb;12(1):55-61.

PMID:
11967138
22.

An antiserum identifying a red cell determinant expressed by Rh:33 and by some "new" depressed Rh phenotypes.

Bizot M, Lomas C, Rubio F, Tippett P.

Transfusion. 1988 Jul-Aug;28(4):342-5.

PMID:
2455369
23.

[Routine use of anti-H of Sambucus ebulus L. on the Groupamatic 360 and Groupamatic 2000].

Soustelle B, Bizot M.

Rev Fr Transfus Immunohematol. 1985 Sep;28(4):345-8. French. No abstract available.

PMID:
4081509
24.

[The importance of HLA typing in cases of disputed paternity].

Seignalet J, Bizot M, Soustelle B, Fourcade J.

J Genet Hum. 1983 Sep;31(3):183-99. French.

PMID:
6581273
25.

[Phenotyping Kell and Duffy antigens by a technic of coagglutination on the Groupamatic G 360].

Soustelle B, Rubio F, Coves F, Bizot M.

Rev Fr Transfus Immunohematol. 1982 Jun;25(3):309-19. French.

PMID:
7111980
26.

[Detection and identification of irregular anti-erythrocyte antibodies with the Groupamatic G 360. Adaptation to the routine].

Soustelle B, Rubio F, Coves F, Bizot M.

Rev Fr Transfus Immunohematol. 1980 Dec;23(6):639-51. French.

PMID:
7221378
27.

[Lymphoproliferative syndrome with cold hemagglutinating, cryoprecipitating monoclonal IgM. Anti-Pr1d specificity].

Richard JL, Vives JF, Bizot M, Jambon C, Schved JF, Vallat G.

Rev Fr Transfus Immunohematol. 1980 Feb;23(1):69-80. French. No abstract available.

PMID:
7375760
28.

[Pseudo-anti-N in patients undergoing maintenance hemodialysis].

Bizot M, Coves F, Rubio F.

Rev Fr Transfus Immunohematol. 1977 Jun;20(2):345-7. French. No abstract available.

PMID:
897471
29.

[Cad antigens in 1976].

Cazal P, Monis M, Bizot M.

Rev Fr Transfus Immunohematol. 1977 Mar;20(1):165-73. French. No abstract available.

PMID:
882780
30.

[Studies on Hempas erythrocytes].

Bizot M.

Rev Fr Transfus Immunohematol. 1975 Dec;18(4):520-1. French. No abstract available.

PMID:
1228862
31.

[Clinical conference: Neonatal icterus from anti-D isoimmunization with negative direct Coombs test].

Rieu D, Bizot M, Monis M, Talb M, Bonnet H, Jean R.

Arch Fr Pediatr. 1975 Jun-Jul;32(6):585. French. No abstract available.

PMID:
810110
32.
33.

[Neonatal hemolytic jaundice caused by anti-D reacting preferentially in an enzyme medium].

Bizot M, Monis M, Rieu D.

Rev Fr Transfus. 1974 Jun;17(2):151-8. French. No abstract available.

PMID:
4217931
34.

[Anti-CAD heteroantibodies in chickens].

Bizot M, Cayla JP.

Rev Fr Transfus. 1972 Jun;15(2):195-202. French. No abstract available.

PMID:
4117359
35.

[Hemagglutinating activity of albumin gland extracts of Helix (Cryptomphalus) aspersa and Helix (Helix) pomatia].

Bizot M.

Rev Fr Transfus. 1971 Dec;14(4):445-53. French. No abstract available.

PMID:
5153039
36.

[Cad antigens].

Cazal P, Monis M, Bizot M.

Nouv Rev Fr Hematol. 1971 Nov-Dec;11(6):909-12. French. No abstract available.

PMID:
4261160
37.

[The Cad antigens and their relation to A antigens].

Cazal P, Monis M, Bizot M.

Rev Fr Transfus. 1971 Sep;14(3):321-34. French. No abstract available.

PMID:
5140904
38.

[Scabies or swimmer's dermatitis].

BIZOT M, RAGUET M, ZORN R.

Concours Med. 1963 Apr 27;85:2705-6. French. No abstract available.

PMID:
13971279
39.

[Antagonism phenomena between various microorganisms: yeasts and bacteria].

BIZOT M.

Presse Med. 1955 Sep 24;63(62):1251-2. French. No abstract available.

PMID:
13266759

Supplemental Content

Support Center